Small RNA-Mediated Epigenetic Myostatin Silencing
Myostatin (Mstn) is a secreted growth factor that negatively regulates muscle mass and is therefore a potential pharmacological target for the treatment of muscle wasting disorders such as Duchenne muscular dystrophy. Here we describe a novel Mstn blockade approach in which small interfering RNAs (s...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2012-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_1a5b9914b7f84a9a95242b647a634a0c | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Thomas C Roberts |e author |
| 700 | 1 | 0 | |a Samir EL Andaloussi |e author |
| 700 | 1 | 0 | |a Kevin V Morris |e author |
| 700 | 1 | 0 | |a Graham McClorey |e author |
| 700 | 1 | 0 | |a Matthew JA Wood |e author |
| 245 | 0 | 0 | |a Small RNA-Mediated Epigenetic Myostatin Silencing |
| 260 | |b Elsevier, |c 2012-01-01T00:00:00Z. | ||
| 500 | |a 2162-2531 | ||
| 500 | |a 10.1038/mtna.2012.15 | ||
| 520 | |a Myostatin (Mstn) is a secreted growth factor that negatively regulates muscle mass and is therefore a potential pharmacological target for the treatment of muscle wasting disorders such as Duchenne muscular dystrophy. Here we describe a novel Mstn blockade approach in which small interfering RNAs (siRNAs) complementary to a promoter-associated transcript induce transcriptional gene silencing (TGS) in two differentiated mouse muscle cell lines. Silencing is sensitive to treatment with the histone deacetylase inhibitor trichostatin A, and the silent state chromatin mark H3K9me2 is enriched at the Mstn promoter following siRNA transfection, suggesting epigenetic remodeling underlies the silencing effect. These observations suggest that long-term epigenetic silencing may be feasible for Mstn and that TGS is a promising novel therapeutic strategy for the treatment of muscle wasting disorders. | ||
| 546 | |a EN | ||
| 690 | |a epigenetic | ||
| 690 | |a muscle degeneration | ||
| 690 | |a myostatin | ||
| 690 | |a siRNA | ||
| 690 | |a transcriptional gene silencing | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Molecular Therapy: Nucleic Acids, Vol 1, Iss C (2012) | |
| 787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S2162253116300804 | |
| 787 | 0 | |n https://doaj.org/toc/2162-2531 | |
| 856 | 4 | 1 | |u https://doaj.org/article/1a5b9914b7f84a9a95242b647a634a0c |z Connect to this object online. |